FDA removes epinephrine from COVID-19 temporary compounding list

The Food and Drug Administration Oct. 15 removed epinephrine from the lists of drugs authorized for temporary compounding during the COVID-19 public health emergency by outsourcing facilities and state-licensed pharmacies or federal facilities not registered as outsourcing facilities.

FDA said epinephrine’s removal is based on increased supplies of FDA-approved epinephrine products used to treat hospitalized COVID-19 patients.

Leave a Reply

Your email address will not be published. Required fields are marked *